Related Experiment Video
Updated: Sep 16, 2025

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Immunotherapy-Associated Renal Dysfunction in Metastatic Cancer: An Emerging Challenge in Onco-Nephrology
Francesco Trevisani1, Andrea Angioi2, Michele Ghidini3
1URI-Urological Research Institute, Department of Urology, Division of Experimental Oncology, IRCCS San Raffaele Hospital, Via Olgettina 60, 20132 Milan, Italy.
Background:
Immune checkpoint inhibitors (ICIs) have significantly modified the management of metastatic cancers; however, their nephrotoxic potential remains underappreciated. While acute kidney injury (AKI) is a known immune-related adverse event, the subacute spectrum of kidney injury-termed acute kidney disease (AKD)-has not been adequately explored in this setting.
Methods:
We conducted a retrospective cohort study in 226 adult patients with metastatic solid tumors who received ICIs between 2017 and 2023 at a single tertiary care center. AKD was defined according to the 2024 "Kidney Disease: Improving Global Outcomes" (KDIGO) criteria. Multivariable logistic regression was used to identify predictors of AKD.
Results:
AKD occurred in 46 patients (20.4%) within 90 days of ICI initiation, with 16 (7.1%) experiencing persistent dysfunction beyond 30 days. Independent predictors of AKD included higher body surface area (OR 8.17, p = 0.03) and baseline use of nonsteroidal anti-inflammatory drugs (OR 29.74, p = 0.014). Baseline antibiotics showed a trend toward association (p = 0.054). Concurrent chemotherapy was associated with a trend toward protection. The predictive model showed good discrimination (AUC 0.778). No significant differences in other grade ≥2 immune-related adverse events were observed between the AKD and non-AKD groups.
Conclusions:
AKD is a frequent and underrecognized renal complication in patients receiving ICIs, with implications for both renal and oncological outcomes. Identifying high-risk patients and integrating longitudinal renal monitoring into immunotherapy care pathways may improve safety and treatment continuity.
Insights
Acute kidney disease (AKD) is a common complication in patients receiving immune checkpoint inhibitors (ICIs). Early identification of high-risk patients is crucial for managing kidney health during cancer immunotherapy.
Area of Science:
- Nephrology
- Oncology
- Immunology
Background:
- Immune checkpoint inhibitors (ICIs) are vital in metastatic cancer treatment but pose nephrotoxic risks.
- Acute kidney injury (AKI) is recognized, but the subacute phase, acute kidney disease (AKD), is understudied in ICI therapy.
Purpose of the Study:
- To investigate the incidence and predictors of acute kidney disease (AKD) in patients undergoing immune checkpoint inhibitor (ICI) therapy.
- To characterize the clinical course and risk factors associated with AKD in this patient population.
Main Methods:
- Retrospective cohort study of 226 adult patients receiving ICIs.
- AKD diagnosis based on 2024 Kidney Disease: Improving Global Outcomes (KDIGO) criteria.
- Multivariable logistic regression identified AKD predictors.
Main Results:
- AKD occurred in 20.4% of patients within 90 days of ICI initiation.
- Higher body surface area and baseline NSAID use were independent AKD predictors (OR 8.17, OR 29.74).
- A predictive model demonstrated good discrimination (AUC 0.778).
Conclusions:
- Acute kidney disease (AKD) is a frequent, underrecognized complication of ICIs.
- Identifying high-risk patients and implementing renal monitoring can improve safety and treatment.
- AKD has implications for both renal function and cancer treatment outcomes.
Related Concept Videos
Kidney Transplant III: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Tumor Immunotherapy
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nephrotic Syndrome I : Introduction
Kidney Transplant II: Surgical Procedure

